Content type

Streamlined Medicine Approval In New Zealand Will Benefit Drugmakers, But Risks In Securing Public Funding Remain

Pharmaceuticals / New Zealand / Fri 08 Mar, 2024

Key View

  • New Zealand’s initiative to fast-track medicine approvals will drive commercial opportunities for drugmakers.
  • The new time limits for approvals will help to correct historical lags in market access and incentivise drugmakers to launch products in New Zealand.
  • While the government remains keen to widen access to patented
Read More

Imminent Recession For New Zealand In 2024

Country Risk / New Zealand / Thu 04 Jan, 2024

Key View

  • Real GDP contracted in Q3 2023, surprising most analysts, including us, to the downside.
  • We have lowered our 2023 growth estimate to 0.5% from 1.3% while our 2024 forecast remains at 1.4%.
  • The weaker economy may prompt the central bank to begin easing sooner than we currently expect in H2 2024.

New Zealand’s GDP contracted by 0

Read More

New Zealand Economic Momentum To Pick Up In 2024

Country Risk / New Zealand / Wed 08 Nov, 2023

Key View

  • We revised our 2023 growth forecast for New Zealand's real GDP growth to 1.3%, up from 1.0% previously, following stronger-than-expected growth in Q223.
  • The economy is set to gain momentum in 2024, driven by looser monetary policy, stronger sentiment, and an expected rebound in tourism. We have adjusted our real GDP growth
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.